Trastuzumab-induced cardiotoxicity may induce reversible damage that is usually transitory and improves with trastuzumab withdrawal. In clinical trials with trastuzumab in the adjuvant setting ...

This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, RAS/RAF/MEK1/2/ERK1/2, MAPK, HER2, PI3K/Akt/mTOR, Wnt/β-catenin, NF-κB ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

[166] The HER2 mAb pertuzumab represents a new class of drugs called dimerization inhibitors; these have the potential to block signaling by ... drugs with other key pathways, will lead to the ...

and the HER2 signaling pathways in breast cancer. The major objectives of this research group are to explore the key oncogenic/signaling networks, develop biomarkers to design tailored targeted ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

We have shown that tumors with HER2 amplification or PI3K mutation are selectively dependent for growth on the PI3K pathway and are sensitive to specific inhibitors of PI3K or AKT. Inhibition of PI3K ...